Pancreatic Carcinoid: A Rare Cause of Diarrheogenic Syndrome

Waisberg, Jaques; Matos, Leandro Luongo de; Santos, Honória Virginea Brom dos; Santos, Angela Batista dos; Reis, Gema Carollo; Capelozzi, Vera Luíza

doi:10.1590/s1807-59322006000200015

Cited by 6 publications

(6 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This program is a new effort among many others in the study of cancer and cancer prevention in Brazil. [51][52][53][54][55][56] Also, such a program would save significant amounts of money spent on surveillance of patients that are negative for a MEN1 mutation.…”

Section: Discussionmentioning

confidence: 99%

The Impact of Clinical and Genetic Screenings on the Management of the Multiple Endocrine Neoplasia Type 1

Lourenço-Jr

Toledo

Coutinho

et al. 2007

Clinics

View full text Add to dashboard Cite

METHODS:The clinical diagnosis of MEN1 was made in accordance with the Consensus on multiple endocrine neoplasias. Mutation analysis of the entire MEN1 tumor suppressor gene and genetic screening of at-risk family members were performed by direct sequencing. To analyze the implementation of genetic diagnosis, the studied patients were separated into 3 groups: MEN1 index cases (group I), clinically diagnosed MEN1 cases (group II), and genetically diagnosed MEN1 cases (group III). RESULTS: In total, 154 individuals were clinically and genetically studied. We identified 12 different MEN1 mutations. Fifty-two MEN1 cases were identified: 13 in group I, 28 in group II, and 11 in group III. The mean age in group III (27.0 years) was significantly lower than in groups I (39.5 years) and II (42.4 years; P = 0.03 and P = 0.01, respectively). Patients in groups I and II mostly presented 2 or 3 MEN1-related tumors, while 81.8% of those in group III presented 1 or no MEN1-related tumor. Additionally, in group III, 45.4% of cases were asymptomatic, and no metastasis or death was verified. Surveillance for MEN1 mutations allowed the exclusion of 102 noncarriers, including a case of MEN1 phenocopy. CONCLUSION: Our data supports the benefits of clinical and genetic screening for multiple endocrine neoplasia type 1 in the management of this syndrome.

show abstract

Section: Discussionmentioning

confidence: 99%

The Impact of Clinical and Genetic Screenings on the Management of the Multiple Endocrine Neoplasia Type 1

Lourenço-Jr

Toledo

Coutinho

et al. 2007

Clinics

View full text Add to dashboard Cite

show abstract

“…A carcinoid tumor of the pancreas (CTP) is a rare neuroendocrine tumor arising from the serotonin-secreting cells (enterochromaffin or Kultscitsky's cells) (1). Modlin et al (2) estimated an incidence of ~0.57% from a 5-decade survey of 13,715 carcinoid tumors located in the gastrointestinal tract, including the pancreas and rectum, and the bronchopulmonary system.…”

Section: Introductionmentioning

confidence: 99%

Carcinoid syndrome from a carcinoid tumor of the pancreas without liver metastases: A case report and literature review

et al. 2017

View full text Add to dashboard Cite

Abstract.A carcinoid tumor of the pancreas (CTP) is a rare pancreatic neoplasm, and usually presents with carcinoid syndrome (CS). CS consists of the classic symptom triad of cutaneous flushing, diarrhea and valvular disease, and occurs in the majority of patients with liver metastases. In the present study, the patient presented with symptoms of CS. A diagnosis of CTP with CS was suspected due to high levels of urine 5-hydroxyindolacetic acid, and this was confirmed by a fine-needle aspiration biopsy. Computed tomography showed extended lymphadenopathy, but no liver metastases. The patient was managed conservatively with octreotide long acting repeatable. To the best of our knowledge, this is the second literature case of CS associated with CTP without liver metastases.

show abstract

“…Gastrin, 29 pg/ml (< 100). Insulin, 11 µU/ml (5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20). Glucagon, 117 and 149 pg/ml (50-250).…”

unclassified

“…VIP, 6 pmol/l (< 30). Somatostatin (SMS), 20 pg/ml (10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25). Neuron-specific enolase (NSE), 2.2 ng/ml (< 13).…”

mentioning

confidence: 99%

Long-standing malignant pancreatic carcinoid treated with octreotide

Varas-Lorenzo

2010

Rev. esp. enferm. dig.

View full text Add to dashboard Cite

A male presented with a metastatic, plasma serotonin-secreting (high 5-HIAA in urine), malignant pancreatic carcinoid with a carcinoid-like syndrome, and was assessed using ultrasounds (US), computerized tomography (CT), magnetic resonance imaging (MRI), endoscopic ultrasonography (EUS) and Octreoscan; he sequentially received chemotherapy, interferon and octreotide, with long-term, 12-year survival after diagnosis. Given this unusual case, the second reported in our country, the overall literature is reviewed.

show abstract

Pancreatic Carcinoid: A Rare Cause of Diarrheogenic Syndrome

Cited by 6 publications

References 12 publications

The Impact of Clinical and Genetic Screenings on the Management of the Multiple Endocrine Neoplasia Type 1

The Impact of Clinical and Genetic Screenings on the Management of the Multiple Endocrine Neoplasia Type 1

Carcinoid syndrome from a carcinoid tumor of the pancreas without liver metastases: A case report and literature review

Long-standing malignant pancreatic carcinoid treated with octreotide

Contact Info

Product

Resources

About